Affymetrix Inc. (NASDAQ: AFFX) and Athletigen Technologies Inc., a direct-to-consumer sports genetics company, today announced a global partnership agreement. Under the agreement, Athletigen will use Affymetrix Axiom ® genotyping platform for its sports-related DNA analysis service.

This Smart News Release features multimedia. View the full release here:

DNA from a saliva sample will be genotyped using Athletigen's DNA microarray which analyzes about 850,000 variants implicated in human athletic performance. The high quality data generated when analyzed with Athletigen's interpretative bioinformatics algorithm enables the delivery of an online, easy-to-use, actionable report on traits relating to athleticism, nutrition, and sports psychology.

"Affymetrix' Axiom platform offers the gold standard for genotyping analysis and, when coupled with our highly curated content selection and interpretative analysis, ensures precision and accuracy for our personalized sports genetics reports to create a blueprint for improving human athletic performance," said Jeremy Koenig, PhD, CEO of Athletigen Technologies Inc.

"We are pleased to support Athletigen's sports genetic offering that empowers athletes and coaches to better understand their athletic traits. Our high fidelity Axiom genotyping platform, due to its high throughput capability, industry-leading genotyping performance, and affordability, is preferred by many large scale biobank projects worldwide and by emerging consumer genomics enterprises for genetic analysis of consumer bio-specimens," said Laurent Bellon, senior vice president and general manager of the Genotyping Business Unit of Affymetrix.

About Athletigen

Athletigen Technologies Inc. is transforming the future for how athletes train. The company provides highly-accurate, sports DNA analysis direct-to-consumers through an easy-to-use, actionable dashboard. Athletigen's sports genetics analysis platform is used by athletes, trainers, coaches, and health professionals to create a personalized blueprint for precision performance. The algorithm-powered platform identifies how your genetics affects athleticism, nutrition, and sports psychology. Athletigen's platform is built on an extensive database of genetic indicators and peer-reviewed research. To learn more visit

About Affymetrix

Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of benchtop research into clinical and routine use for human health and wellness. Affymetrix provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies as well as leading academic, government, and non-profit research institutes in their quest to use biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 94,000 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, San Diego, Vienna and Singapore. Affymetrix has about 1,100 employees and maintains sales and distribution operations worldwide. For more information about Affymetrix, please visit

Forward-looking statements

All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2014, and other SEC reports for subsequent quarterly periods.

PLEASE NOTE: Affymetrix, the Affymetrix logo, and Axiom trademarks are the property of Affymetrix, Inc. All other trademarks are the property of their respective owners.

View source version on

Copyright Business Wire 2010